IP Verse

Use Of Cladribine For Treating Neuromyelitis Optica - EP3099307

The patent EP3099307 was granted to Chord Therapeutics on Jul 29, 2020. The application was originally filed on Jan 27, 2015 under application number EP15702549A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3099307

CHORD THERAPEUTICS
Application Number
EP15702549A
Filing Date
Jan 27, 2015
Status
Patent Maintained As Amended
Jun 26, 2020
Publication Date
Jul 29, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MERCK PATENTJul 18, 2018- -

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0173059
DESCRIPTIONEP2263678
DESCRIPTIONUS5208327
DESCRIPTIONUS5506214
DESCRIPTIONWO2004087100
INTERNATIONAL-SEARCH-REPORTEP2263678
INTERNATIONAL-SEARCH-REPORTUS2010092478
OPPOSITIONUS2010239580
OPPOSITIONWO2004087100
OPPOSITIONWO2006067141
OPPOSITIONWO2008097596
OPPOSITIONWO2011080344

Non-Patent Literature (NPL) Citations (31) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AWAD A.; STUVE 0., CURRENT NEUROPHARMACOLOGY, (2011), vol. 2, pages 417 - 428
DESCRIPTION- GHOSH A. ET AL., NEUROLOGY, (2002), vol. 59, pages 1290 - 1291
DESCRIPTION- LAUGEL B. ET AL., J. NEUROIMMUNOL;, (2011), vol. 240-241, pages 52 - 57
DESCRIPTION- OHTA A; SITKOVSKY M., NATURE, (2001), vol. 414, pages 916 - 20
DESCRIPTION- ROBINS ET AL., J. AM. CHEM.SOC., (1984), vol. 106, page 6379
DESCRIPTION- SHIMIZU Y. ET AL., J. NEUROL., (2008), vol. 255, pages 305 - 307
DESCRIPTION- UZAWA A. ET AL., EUR. J. NEUROL.,, (2010), vol. 17, pages 672 - 676
DESCRIPTION- WINGERCHUK, D.M. ET AL., NEUROLOGY, (2006), vol. 66, no. 10, pages 1485 - 1489
INTERNATIONAL-SEARCH-REPORT- HOLMOY T ET AL, "The Immunological Basis for Treatment of Multiple Sclerosis", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 66, no. 4, doi:10.1111/J.1365-3083.2007.01982.X, ISSN 0300-9475, (20071001), pages 374 - 382, (20070716), XP002593548 [A] 1-21 * page 376, column 1, paragraph 3 *
INTERNATIONAL-SEARCH-REPORT- A. UZAWA ET AL, "Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis", EUROPEAN JOURNAL OF NEUROLOGY, (20100501), vol. 17, no. 5, doi:10.1111/j.1468-1331.2009.02897.x, ISSN 1351-5101, pages 672 - 676, XP055172324 [A] 1-21 * the whole document *
INTERNATIONAL-SEARCH-REPORT- D. M. WINGERCHUK ET AL, "Revised diagnostic criteria for neuromyelitis optica", NEUROLOGY, (20060522), vol. 66, no. 10, doi:10.1212/01.wnl.0000216139.44259.74, ISSN 0028-3878, pages 1485 - 1489, XP055049858 [A] 1-21 * the whole document *
OPPOSITION- AWAD et al., "Idiopathic transverse myelitis and Neuromyelitis optica: Clinical profiles, Pathophysiology and Therapeutic Choices", Current Neuropharmacology, (20110000), vol. 9, pages 417 - 428, XP055517767
OPPOSITION- BELLANGER et al., "Multiple Sclerosis Treatment Update", US Pharmacist, (20120100), vol. 37, no. 1, pages 42 - 45, XP055517829
OPPOSITION- CAMILA RODRIGUES DE ALMEIDA, "Frequencia do anticorpo IGG NMO em pacientes com neuromielite optica no rio de janeiro e sua influencia no prognostico da enfermidade", PhD thesis, Rio de Janeiro, (20150000), XP055517802
OPPOSITION- CHONG et al., "A Review of Multiple Sclerosis with Asian Perspective", Med J Malaysia, (20081200), vol. 63, no. 5, pages 356 - 361, XP055517823
OPPOSITION- GIOVANNONI et al., "A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis", N. Engl. J. Med., (20100000), vol. 362, pages 416 - 426, XP002601628
OPPOSITION- GROSSMANN et al., "Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics", EPMA Journal, (20100000), vol. 1, pages 317 - 327, XP055517791
OPPOSITION- GÜRCAN et al., "A review of the current use of rituximab in autoimmune diseases", International Immunopharmacology, (20090000), vol. 9, pages 10 - 15, XP055517814
OPPOSITION- HARTUNG et al., "Development of oral cladribine for the treatment of multiple sclerosis", J Neurol., (20100000), vol. 257, pages 163 - 170, XP019781072
OPPOSITION- JURYNCZYK et al., "Expert opinions on the diagnosis and treatment of patients with AQP4-negative NMO/MS overlapping syndromes", J Neurol Neurosurg Psychiatry, London, (20150910), vol. 86, XP055517776
OPPOSITION- KIMBROUGH et al., "Treatment of neuromyelitis optica: Review and recommendations", Multiple Sclerosis and Related Disorders, (20120000), vol. 1, pages 180 - 187, XP055517787
OPPOSITION- KIM et al., "Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4", Multiple Sclerosis Journal, (20120000), vol. 18, no. 5, pages 578 - 586, XP055517772
OPPOSITION- REJDAK et al., "Multiple sclerosis: a practical overview for clinicians", British Medical Bulletin, (20100000), vol. 95, pages 79 - 104, XP055517759
OPPOSITION- ROSENZWEIG et al., "Disease-modifying therapy in adult relapsing remitting multiple sclerosis", Formulary, (20100800), vol. 45, pages 252 - 262, XP008139198
OPPOSITION- TREBST et al., "Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS", J. Neurol., (20140000), vol. 261, pages 1 - 16, XP055517792
OPPOSITION- JURYNCZYK et al., "Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes", J. Neurol., (20160000), vol. 263, no. 1, pages 140 - 149, XP035612094
OPPOSITION- LAUGEL et al., "Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity", J. of Neuroimmunology, (20110000), vol. 240, no. 241, pages 52 - 57, XP028335834
OPPOSITION- MITOSEK-SZEWCZAK et al., "Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis", Journal of the Neurological Sciences, (20130000), vol. 332, pages 35 - 40, XP055316637
OPPOSITION- WINGERCHUK et al., "The spectrum of neuromyelitis optica", Lancet Neurol., (20070000), vol. 6, pages 805 - 815, XP022197462
OPPOSITION- WINGERCHUK et al., "Revised diagnostic criteria for neuromyelitis optica", Neurobiology, (20060500), vol. 66, pages 1485 - 1489, XP055049858
OPPOSITION- SA et al., "Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders", Current Nanoscience, (20110000), vol. 7, pages 7 - 20, XP055172572

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents